Related Experiment Videos
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
1Department of Molecular and Cell Biology, University of California, Berkeley 94720.
Abstract:
A variety of tumors are potentially immunogenic but do not stimulate an effective anti-tumor immune response in vivo. Tumors may be capable of delivering antigen-specific signals to T cells, but may not deliver the costimulatory signals necessary for full activation of T cells. Expression of the costimulatory ligand B7 on melanoma cells was found to induce the rejection of a murine melanoma in vivo. This rejection was mediated by CD8+ T cells; CD4+ T cells were not required. These results suggest that B7 expression renders tumor cells capable of effective antigen presentation, leading to their eradication in vivo.
Insights
Tumors can be immunogenic but fail to trigger an effective immune response. Enhancing tumor cells with B7 costimulatory ligands promotes T cell activation and tumor rejection in vivo.
Area of Science:
- Immunology
- Oncology
- Cancer Immunology
Background:
- Tumors possess immunogenic potential but often evade immune surveillance.
- Tumors may present antigens but lack essential costimulatory signals for T cell activation.
Purpose of the Study:
- To investigate the role of costimulatory ligand B7 in overcoming tumor-induced immune tolerance.
- To determine if B7 expression can elicit an effective anti-tumor immune response in vivo.
Main Methods:
- Melanoma cells engineered to express the B7 costimulatory ligand.
- In vivo studies using a murine melanoma model.
- Analysis of T cell populations (CD8+ and CD4+) mediating tumor rejection.
Main Results:
- Expression of B7 on melanoma cells induced rejection of the tumor in vivo.
- Tumor rejection was mediated by CD8+ cytotoxic T lymphocytes.
- CD4+ T cells were not essential for B7-induced tumor eradication.
Conclusions:
- B7 costimulatory ligand expression enhances tumor cell antigen presentation capabilities.
- B7 expression can render tumor cells susceptible to immune-mediated eradication.
- Targeting costimulatory pathways offers a potential strategy for cancer immunotherapy.